Comparison of regional blood flow values measured by radioactive and fluorescent microspheres

Fluorescent microspheres (FM) have become an attractive alternative to radioactive microspheres (RM) for the measurement of regional blood flow (RBF). The aim of the present study was to investigate the comparability of both methods by measuring RBF with FM and RM. Eight anaesthetised pigs received simultaneous, left atrial injections of FM and RM with a diameter of 15 mum at six different time points. Blood reference samples were collected from the descending aorta. RBF was determined in tissue samples of the myocardium, spleen and kidneys of all 8 animals. After radioactivity of the tissue samples was determined, the samples were processed automatically for measuring fluorescence using a recently developed filter device (SPU). RBF was calculated with both the isotope and spectrometric data of both methods for each sample resulting in a total of 10,512 blood flow values. The comparison of the RBF values yielded high linear correlation (mean r(2) = 0.95 +/- 0.03 to 0.97 +/- 0.02) and excellent agreement (bias 5.4-6.7%, precision 9.9-16.5%) of both methods. Our results indicate the validity of MS and of the automated tissue processing technique by means of the SPU. Copyright (C) 2002 S. Karger AG, Basel

Milk Production

Guide to milk production discusses the udder, teats, glands, milk secretion, the duct system, milk let down, milking procedures, and number of milking units

Students Respond To The Use Of Instructional Technology In The Accounting Information Systems Classroom

A SERVQUAL-inspired instrument measured students’ satisfaction with technology tools used in AIS classrooms; 151 students in six schools participated.  Student in-class computer activities generated the highest satisfaction among students, live software demonstration the least.  Satisfaction varied little by gender or age group.  Student in-class computer activities showed the most reaction of satisfaction to usage rates, and in all cases greater usage led to higher satisfaction.  In some instances, the satisfaction score for a question differed across technology groups, but these differences are not generalizable.  Factor analysis largely supports the a priori loading of satisfaction items into five SERVQUAL dimension

Are Privacy Policies More Clear and Conspicuous

ABSTRACT Concer

Exploiting asynchrony from exact forward recovery for DUE in iterative solvers

This paper presents a method to protect iterative solvers from Detected and Uncorrected Errors (DUE) relying on error detection techniques already available in commodity hardware. Detection operates at the memory page level, which enables the use of simple algorithmic redundancies to correct errors. Such redundancies would be inapplicable under coarse grain error detection, but become very powerful when the hardware is able to precisely detect errors. Relations straightforwardly extracted from the solver allow to recover lost data exactly. This method is free of the overheads of backwards recoveries like checkpointing, and does not compromise mathematical convergence properties of the solver as restarting would do. We apply this recovery to three widely used Krylov subspace methods, CG, GMRES and BiCGStab, and their preconditioned versions. We implement our resilience techniques on CG considering scenarios from small (8 cores) to large (1024 cores) scales, and demonstrate very low overheads compared to state-of-the-art solutions. We deploy our recovery techniques either by overlapping them with algorithmic computations or by forcing them to be in the critical path of the application. A trade-off exists between both approaches depending on the error rate the solver is suffering. Under realistic error rates, overlapping decreases overheads from 5.37% down to 3.59% for a non-preconditioned CG on 8 cores.This work has been partially supported by the European Research Council under the European Union's 7th FP, ERC Advanced Grant 321253, and by the Spanish Ministry of Science and Innovation under grant TIN2012-34557. L. Jaulmes has been partially supported by the Spanish Ministry of Education, Culture and Sports under grant FPU2013/06982. M. Moreto has been partially supported by the Spanish Ministry of Economy and Competitiveness under Juan de la Cierva postdoctoral fellowship JCI-2012-15047. M. Casas has been partially supported by the Secretary for Universities and Research of the Ministry of Economy and Knowledge of the Government of Catalonia and the Co-fund programme of the Marie Curie Actions of the European Union's 7th FP (contract 2013 BP B 00243).Peer ReviewedPostprint (author's final draft

Novel technologies and emerging biomarkers for personalized cancer immunotherapy

The culmination of over a century's work to understand the role of the immune system in tumor control has led to the recent advances in cancer immunotherapies that have resulted in durable clinical responses in patients with a variety of malignancies. Cancer immunotherapies are rapidly changing traditional treatment paradigms and expanding the therapeutic landscape for cancer patients. However, despite the current success of these therapies, not all patients respond to immunotherapy and even those that do often experience toxicities. Thus, there is a growing need to identify predictive and prognostic biomarkers that enhance our understanding of the mechanisms underlying the complex interactions between the immune system and cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) reconvened an Immune Biomarkers Task Force to review state of the art technologies, identify current hurdlers, and make recommendations for the field. As a product of this task force, Working Group 2 (WG2), consisting of international experts from academia and industry, assembled to identify and discuss promising technologies for biomarker discovery and validation. Thus, this WG2 consensus paper will focus on the current status of emerging biomarkers for immune checkpoint blockade therapy and discuss novel technologies as well as high dimensional data analysis platforms that will be pivotal for future biomarker research. In addition, this paper will include a brief overview of the current challenges with recommendations for future biomarker discovery

Cognitive dysfunction in naturally occurring canine idiopathic epilepsy

Globally, epilepsy is a common serious brain disorder. In addition to seizure activity, epilepsy is associated with cognitive impairments including static cognitive impairments present at onset, progressive seizure-induced impairments and co-morbid dementia. Epilepsy occurs naturally in domestic dogs but its impact on canine cognition has yet to be studied, despite canine cognitive dysfunction (CCD) recognised as a spontaneous model of dementia. Here we use data from a psychometrically validated tool, the canine cognitive dysfunction rating (CCDR) scale, to compare cognitive dysfunction in dogs diagnosed with idiopathic epilepsy (IE) with controls while accounting for age. An online cross-sectional study resulted in a sample of 4051 dogs, of which n = 286 had been diagnosed with IE. Four factors were significantly associated with a diagnosis of CCD (above the diagnostic cut-off of CCDR ≥50): (i) epilepsy diagnosis: dogs with epilepsy were at higher risk; (ii) age: older dogs were at higher risk; (iii) weight: lighter dogs (kg) were at higher risk; (iv) training history: dogs with more exposure to training activities were at lower risk. Impairments in memory were most common in dogs with IE, but progression of impairments was not observed compared to controls. A significant interaction between epilepsy and age was identified, with IE dogs exhibiting a higher risk of CCD at a young age, while control dogs followed the expected pattern of low-risk throughout middle age, with risk increasing exponentially in geriatric years. Within the IE sub-population, dogs with a history of cluster seizures and high seizure frequency had higher CCDR scores. The age of onset, nature and progression of cognitive impairment in the current IE dogs appear divergent from those classically seen in CCD. Longitudinal monitoring of cognitive function from seizure onset is required to further characterise these impairments

SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Since the publication of the Society for Immunotherapy of Cancer\u27s (SITC) original cancer immunotherapy biomarkers resource document, there have been remarkable breakthroughs in cancer immunotherapy, in particular the development and approval of immune checkpoint inhibitors, engineered cellular therapies, and tumor vaccines to unleash antitumor immune activity. The most notable feature of these breakthroughs is the achievement of durable clinical responses in some patients, enabling long-term survival. These durable responses have been noted in tumor types that were not previously considered immunotherapy-sensitive, suggesting that all patients with cancer may have the potential to benefit from immunotherapy. However, a persistent challenge in the field is the fact that only a minority of patients respond to immunotherapy, especially those therapies that rely on endogenous immune activation such as checkpoint inhibitors and vaccination due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers for each immunotherapy strategy, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement of immunotherapy. In this document, we summarize and update established biomarkers, guidelines, and regulatory considerations for clinical immune biomarker development, discuss well-known and novel technologies for biomarker discovery and validation, and provide tools and resources that can be used by the biomarker research community to facilitate the continued development of immuno-oncology and aid in the goal of durable responses in all patients